Results 111 to 120 of about 9,532 (171)

Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China. [PDF]

Cancers (Basel)
Gao S, Zhuang J, Liu A, Wang D, Wang W, Li X, Wang Z, Fang M, Gong M, Jia Z, Wu S, Xu Z, Wang G, Bao L.   +13 more
europepmc   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma. [PDF]

FEBS J
Fuentes-Lacouture MC, Nandana D, Ramasamy K, Thakurta A.   +3 more
europepmc   +1 more source

Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting. [PDF]

Open Heart
Henriques Peck O, McCoubrey A, Snowden JA, Wechalekar A, Travers J, Lees JS, Petrie MC, Lang NN.   +7 more
europepmc   +1 more source

Early Adherence to Immunomodulators in Multiple Myeloma: Retrospective Observations from a Safety-Net Hospital. [PDF]

Curr Oncol
Ononogbu O, Mohr S, Khalid J, Glass A, Emovon J, Ma H, Alkhatib Y, Correa A.   +7 more
europepmc   +1 more source

Case Report: Central nervous system relapse treated with elranatamab after prior BCMA and GPRC5D directed therapies in relapsed/refractory multiple myeloma. [PDF]

Front Oncol
Pérez-Calle R, Domingo-González A, López-Lorenzo JL, Bastidas-Tamayo JF, Gutiérrez-San José B, Mata-Serna R, García-Corral B, Santiago-Álvarez JL, Vega-Achabal G, Llamas-Sillero P, Askari E.   +10 more
europepmc   +1 more source

Anti-CRISPR-mediated continuous directed evolution of CRISPR-Cas9 in human cells. [PDF]

Proc Natl Acad Sci U S A
Sabol AL, Mengiste AA, Singh P, Sreekanth V, Hendel SJ, Tran MTN, Barybin AM, Chaudhary S, Harris RM, Liivak KE, Severance ZC, Locicero CM, Kailass K, Lee C, Xu LQ, Butty VL, Choudhary A, Shoulders MD.   +17 more
europepmc   +1 more source

Persistence to Multiple Myeloma Treatments Given at First Relapse-Results From the Australian Real-World OPTIMISE Study. [PDF]

EJHaem
Buescher F, Su S, Waterhouse B, Pinto C.
europepmc   +1 more source

EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway. [PDF]

Haematologica
Li Y, Wilson A, Chrisochoidou Y, Martin S, Bird S, Morales S, Leiro M, Kozik Z, Crump NT, Roumeliotis TI, Choudhary J, Pawlyn C.   +11 more
europepmc   +1 more source

Accelerated synthesis of immunomodulatory imide drugs and their derivatives via continuous flow chemistry. [PDF]

Commun Chem
Hou T, Huang J, Li Y, Zhu Y, You H, Chen FE.   +5 more
europepmc   +1 more source

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China. [PDF]

Front Oncol
Jiang W, Zhong W, Yu J, Tang Y, Guo Q.
europepmc   +1 more source